School of Medicine


Showing 2,881-2,900 of 4,924 Results

  • Nicholas Melosh

    Nicholas Melosh

    Professor of Materials Science and Engineering

    BioThe Melosh group explores how to apply new methods from the semiconductor and self-assembly fields to important problems in biology, materials, and energy. We think about how to rationally design engineered interfaces to enhance communication with biological cells and tissues, or to improve energy conversion and materials synthesis. In particular, we are interested in seamlessly integrating inorganic structures together with biology for improved cell transfection and therapies, and designing new materials, often using diamondoid molecules as building blocks.
    My group is very interested in how to design new inorganic structures that will seamless integrate with biological systems to address problems that are not feasible by other means. This involves both fundamental work such as to deeply understand how lipid membranes interact with inorganic surfaces, electrokinetic phenomena in biologically relevant solutions, and applying this knowledge into new device designs. Examples of this include “nanostraw” drug delivery platforms for direct delivery or extraction of material through the cell wall using a biomimetic gap-junction made using nanoscale semiconductor processing techniques. We also engineer materials and structures for neural interfaces and electronics pertinent to highly parallel data acquisition and recording. For instance, we have created inorganic electrodes that mimic the hydrophobic banding of natural transmembrane proteins, allowing them to ‘fuse’ into the cell wall, providing a tight electrical junction for solid-state patch clamping. In addition to significant efforts at engineering surfaces at the molecular level, we also work on ‘bridge’ projects that span between engineering and biological/clinical needs. My long history with nano- and microfabrication techniques and their interactions with biological constructs provide the skills necessary to fabricate and analyze new bio-electronic systems.


    Research Interests:
    Bio-inorganic Interface
    Molecular materials at interfaces
    Self-Assembly and Nucleation and Growth

  • Fernando S. Mendoza

    Fernando S. Mendoza

    Associate Dean of Minority Advising and Programs and Professor of Pediatrics (General Pediatrics) at the Lucile Salter Packard Children's Hospital, Emeritus

    Current Research and Scholarly InterestsI have two research interests: childhood health disparities and workforce diversity. My research on childhood health disparities centers on Latino and immigrant children with a focus on early childhood health and development. My work in workforce diversity examines the pipeline for diversity in academic pediatrics, with special attention on the pipeline for underrepresent minorities.

  • Joshua Menke

    Joshua Menke

    Clinical Assistant Professor, Pathology

    BioDr. Joshua Menke completed his hematopathology fellowship at Stanford and a cytopathology fellowship at the University of California, San Francisco (UCSF). His clinical and research interests lie at the intersection of hematopathology, cytopathology, and advanced single-cell and cell-free diagnostic techniques. As the Associate Section Director of Clinical Flow Cytometry at Stanford, Dr. Menke is developing and validating new minimal residual disease assays for detecting low levels of myeloid and lymphoid neoplasms in the post-treatment setting, as well as multiple other 12-color flow assays with the latest markers for routine phenotyping.

    Dr. Menke is the recipient of the Paul E. Strandjord Young Investigator Award from the Academy of Clinical Laboratory Scientists and the Laurence J. Marton Award for Excellence in Research from UCSF for his translational work on CALR mutations at the UCSF Molecular Diagnostics Laboratory. Dr. Menke is a founding member of the Cytology-Hematopathology Interinstitutional Collaboration (CHIC), which aims to study the performance of cytology samples in diagnosing lymphoma across large datasets from five academic institutions. He currently chairs this group, leading large clinical research studies.

  • Vinod Menon

    Vinod Menon

    Rachael L. and Walter F. Nichols, MD, Professor and Professor, by courtesy, of Education and of Neurology and Neurological Sciences

    Current Research and Scholarly InterestsEXPERIMENTAL, CLINICAL AND THEORETICAL SYSTEMS NEUROSCIENCE

    Cognitive neuroscience; Systems neuroscience; Cognitive development; Psychiatric neuroscience; Functional brain imaging; Dynamical basis of brain function; Nonlinear dynamics of neural systems.

  • Antonio Meola, MD, PhD

    Antonio Meola, MD, PhD

    BioAntonio Meola M.D. Ph.D graduated Summa cum Laude and Research Honors at the University of Pisa, Italy, in 2008, and completed his residency training in Neurosurgery at the same Institution in July 2015. Dr Meola attended a Ph.D. program at the University of Florence, Italy, where he discussed a doctoral thesis entitled "A New Head-Mounted Display-based Augmented Reality System in Neurosurgical Oncology: a study on phantom".
    Since 2/2014 to 1/2015 Dr Meola completed a Research Fellowship in Neurosurgical anatomy at the University of Pittsburgh Medical Center (UPMC), under the Direction of Dr. Juan C. Fernandez-Miranda. The main focus of his research was the surgical neuroanatomy of the white matter tracts of the human brain.
    Since 7/2015 to 6/2016 Dr Meola served as Clinical Fellow in Image-Guided Neurosurgery at the Brigham and Women's Hospital, Harvard Medical School, in Boston, MA (Director: Dr. Alexandra J. Golby M.D.). During the fellowship, he focused on the clinical application and integration of advanced imaging techniques, including intraoperative-MRI, intraoperative US, functional MRI, tractography.
    Since 7/2016 to 6/2017 Dr Meola completed a Neurosurgical Oncology Fellowship at the Cleveland Clinic in Cleveland, OH, devoting his efforts to minimally-invasive neurosurgical techniques, such as Laser interstitial Thermal Therapy (LITT) and stereotactic radiosurgery (Gamma Knife), as well as to awake neurosurgery.
    Starting 7/2017, Dr Meola joined the Department of Neurosurgery at Stanford. Dr. Meola mainly focuses on conventional and innovative treatments for brain and skull base tumors, including both surgery and stereotactic radiosurgery (CyberKnife).

  • Mark Mercola

    Mark Mercola

    Professor of Medicine (Cardiovascular) and, by courtesy, of Chemical and Systems Biology

    BioDr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.

    Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.

    Prof. Mercola received an NIH MERIT award for his work on heart formation. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, Phospholamban Foundation and Fondation Leducq.

  • Thomas Charles Merigan M.D.

    Thomas Charles Merigan M.D.

    George E. and Lucy Becker Professor of Medicine, Emeritus

    Current Research and Scholarly InterestsI am now emeritus and only participate in university activities through advising my former trainees who have joined the faculty.

  • Anna H. Messner, MD

    Anna H. Messner, MD

    Professor of Otolaryngology-Head and Neck Surgery (Pediatrics) at the Stanford University Medical Center and the Lucile Salter Packard Children's Hospital, Emerita

    Current Research and Scholarly Interests-- Obstructive sleep apnea in children
    -- Postoperative tonsillectomy care
    -- Ankyloglossia
    -- Medical Education

  • Everett Meyer

    Everett Meyer

    Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy), of Pediatrics (Stem Cell Transplantation) and, by courtesy, of Surgery (Abdominal Transplantation)

    Current Research and Scholarly InterestsResearch focus in T cell immunotherapy and T cell immune monitoring using high-throughput sequencing and genomic approaches, with an emphasis on hematopoietic stem cell transplantation, the treatment of graft-versus-host disease and immune tolerance induction.

  • Timothy Meyer

    Timothy Meyer

    Stanford University Professor of Nephrology, Emeritus

    Current Research and Scholarly InterestsInadequate removal of uremic solutes contributes to widespread illness in the more than 500,000 Americans maintained on dialysis. But we know remarkably little about these solutes. Dr. Meyer's research efforts are focused on identifying which uremic solutes are toxic, how these solutes are made, and how their production could be decreased or their removal could be increased. We should be able to improve treatment if we knew more about what we are trying to remove.